this study aimed to assess the treatment response, short-term overall survival (os) and safety profiles of drug-eluting beads transarterial chemoembolization (deb-tace) in patients with secondary liver cancer.
fifty-five patients with secondary liver cancer underwent deb-tace were enrolled in this prospective cohort study. treatment response was assessed by modified response evaluation criteria in solid tumors (mrecist). os was calculated from the time of deb-tace operation until the date of death.
the complete response (cr) and objective response rate (orr) at 1-3 months post deb-tace were 12.7% and 67.3 %. mean os was 383 d (95% ci: 360-406), and 6-month os rate was 93.4%±3.7%.subgroup analysis revealed previous conventional tace (ctace) treatment was correlated with worse orr (p=0.028), and it was a risk factor for orr achievement (p=0.021). as for liver function, the percentages of abnormal tp (p=0.031), tbil (p=0.022), alt (p=0.002) and ast (p=0.035) were increased at 1 week post deb-tace compared to baseline, while these four indexes returned to baseline (all p>0.05) at 1-3 months post deb-tace. as to safety profiles, 41 (66.1%), 28 (45.2%), 17 (27.4%), 8 (12.9%) and 6 (9.7%) cases had pain, vomiting, fever, nausea and other adverse events (aes) respectively during deb-tace operation, while 26 (41.9%), 9 (14.5%), 8 (12.9%), 4 (6.5%), 1 (1.6%) and 2 (3.2%) cases had pain, fever, vomiting, nausea, bone marrow toxicity and other aes respectively at 1 month after deb-tace operation.
deb-tace术后1-3个月的完全缓解率(cr)和客观缓解率(orr)分别为12.7%和67.3%。平均os为383 d (95% ci: 360 406)，6个月os为93.4%±3.7%。亚组分析显示，既往常规tace (ctace)治疗与orr较差相关(p=0.028)，是影响orr的危险因素之一(p=0.021)。在肝功能方面，与基线相比，deb-tace术后1周tp异常(p=0.031)、tbil异常(p=0.022)、alt异常(p=0.002)及ast异常(p=0.035)的百分比均升高，而在deb-tace术后1-3个月，这4项指标均恢复到基线水平(p值均>0.05)。安全性方面，在进行deb-tace治疗期间，疼痛、呕吐、发烧、恶心和其他不良事件(aes)分别为41例 (66.1%)、28例 (45.2%)、17例(27.4%)、8例(12.9%)、6例(9.7%)，而deb-tace术后1个月，疼痛、发烧、呕吐、恶心、骨髓毒性和其他aes分别为26例(41.9%)、9例(14.5%)、8例(12.9%)、4例(6.5%)、1例(1.6%)、2例(3.2%)。
deb-tace was efficient and well tolerated in treating patients with secondary liver cancer.